Genitourinary Cancer
News
DNA repair mutations crop up often in mPC
Key clinical point: Germline mutations in DNA repair genes are potential targets for therapy in men with metastatic prostate cancer. Major finding...
News
Cisplatin-based chemo may be linked to hearing loss
Key clinical point: In male patients with adult-onset germ cell tumors, cisplatin-based chemotherapy may be associated with hearing loss. Major...
Original Report
Group-based psychosocial services: assessing outpatient oncology needs
News
RT + ADT linked with improved survival in mPC
Key clinical point: The addition of radiotherapy (RT) to androgen deprivation therapy (ADT) was associated with improved survival in men with...
Conference Coverage
Endorectal balloons decrease prostate radiation’s rectal and bowel sequelae
Endorectal balloons appeared to protect against rectal complications from prostate cancer radiation in a small randomized trial from Australia...
News
Early results promising for pembrolizumab in combination regimens for NSCLC
Key clinical point: Overall response rates ranged from 30% to 71% when pembrolizumab was added to chemotherapy combinations or paired with an R2...
News
Pembrolizumab paired with immunostimulator is safe and tolerable
Combining an immunostimulator with pembrolizumab had good tolerability and safety, in a small phase Ib study.
News
Immune agonist, checkpoint inhibitor combo shows good tolerability
Combining two immunotherapies, one inhibiting immune suppression and the other stimulating immune activation, is well tolerated and shows activity...
News
No OS benefit with tasquinimod in mCRPC
Key clinical point: Tasquinimod improved progression-free survival (PFS) but not overall survival (OS) in men with metastatic castration-resistant...
News
Baseline PSA at midlife predicts lethal prostate cancer
Key clinical point: Prostate-specific antigen levels at midlife predicted subsequent lethal prostate cancer in men who participated in the...
News
Atezolizumab has good showing as first-line therapy in urothelial cancer
Key clinical point: Atezolizumab is efficacious when used as first-line therapy in advanced urothelial cancer. Major finding: The overall response...